Financials

Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
13.29
ratio cours/chiffre d'affaires
0.94

Related tickers

#NomPrix24h %7 jours %1M %1 an %Cap Boursière7 Derniers Jours
3174
CGC
Canopy Growth Corporation - Common Shares
0.75 USD+5.63%+11.94%-16.67%-34.78%317.28 M USD
3202
ACB
Aurora Cannabis Inc. - Common Shares
5.24 USD+1.55%+28.43%+15.16%+17.23%308.89 M USD
3299
BIOA
BioAge Labs, Inc. - Common Stock
5.95 USD-0.17%0.00%-7.32%-20.56%273.09 M USD
3300
ANIK
Anika Therapeutics Inc. - Common Stock
20.40 USD+4.88%-5.38%+3.40%+106.69%273.01 M USD

Frequently asked questions about Emergent Biosolutions, Inc.

What is the Emergent Biosolutions, Inc. stock price today?

The current price of Emergent Biosolutions, Inc. (EBS) is 5.90. Over the past 24 hours, the stock has changed by -5.60%. Follow the EBS chart for real-time price dynamics.

What is the stock ticker of Emergent Biosolutions, Inc.?

Emergent Biosolutions, Inc. trades under the ticker EBS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Emergent Biosolutions, Inc. stock going up?

EBS has changed by -16.78% over the last week, -17.60% over the last month, and -44.96% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Emergent Biosolutions, Inc.?

Emergent Biosolutions, Inc. currently has a market capitalization of 303.35 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Emergent Biosolutions, Inc. earnings last quarter?

Last quarter, Emergent Biosolutions, Inc. reported earnings of -0.64 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Emergent Biosolutions, Inc. revenue for the last quarter?

Emergent Biosolutions, Inc. reported quarterly revenue of 110 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Emergent Biosolutions, Inc. net income for the last quarter?

Emergent Biosolutions, Inc. reported net income of -32.7 M for the last quarter. The previous quarter showed -180.2 M, which means net income changed by +81.85%.

How many employees does Emergent Biosolutions, Inc. have?

As of the latest available data, Emergent Biosolutions, Inc. has 900 employees. Workforce size can provide additional context about the company's scale and operations.

What is Emergent Biosolutions, Inc. EBITDA?

Emergent Biosolutions, Inc. EBITDA is -159.9 M, and its EBITDA margin is -145.36%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Emergent Biosolutions, Inc. stock?

You can buy Emergent Biosolutions, Inc. (EBS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Emergent Biosolutions, Inc. stock?

Investing in Emergent Biosolutions, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the EBS chart and related analysis on metatrader.com as part of your research.

Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. est une multinationale américaine spécialisée dans le secteur biopharmaceutique, dont le siège social est situé à Gaithersburg, dans le Maryland. Elle développe des vaccins et des traitements à base d'anticorps contre les maladies infectieuses et les surdoses d'opioïdes, et fournit des dispositifs médicaux destinés à la biodéfense. Parmi les produits de la société figurent le controversé BioThrax, le seul vaccin contre l'anthrax autorisé par la Food and Drug Administration américaine, et le Narcan, destiné au traitement d'urgence des surdoses d'opioïdes. La société fabrique également des médicaments contre des maladies infectieuses telles que le choléra et la typhoïde. Pendant la pandémie de COVID-19, Emergent BioSolutions a également produit les vaccins Johnson & Johnson/Janssen et Oxford–AstraZeneca dans l'une de ses usines ; cependant, cette production a été marquée par des contaminations et d'autres problèmes de fabrication, et des millions de doses de vaccin ont dû être mises au rebut.

Nouvelles